This data package is about anticoagulant therapy. It includes following datasets: patients with and without hematoma enlargement, chronic care management differences and patient outcomes in anticoagulant clinics, participant characteristics anticoagulants randomized trial, pulmonary embolism thrombolysis treatment and its complications.
This data package is a collection of numerous studies related to anticoagulation therapy. The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed a study on behalf of IGNITE (Initiative of German Neuro-intensive Trial Engagement). The study investigated the association of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and the effects of OAC resumption. Another study compared outcome for patients using two different mode of reversal treatments: (1) Fresh Frozen Plasma (FFP), and (2) Prothrombin Complex Concentrates (PCC). A research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy. The data were subjected to regression analysis to identify to what extent the differences in patient outcomes are associated with chronic care management activities. Another study was performed to identify the differences in patient outcomes and their relationship with chronic care management of oral anticoagulant. The goal of another study was to perform a systematic review of the literature and determine pre-specified inclusion criteria based on relevant studies, which are as follows: randomized controlled design in patients with PE evaluating thrombolytic therapy as an intervention; a comparator group that included any of the following agents: low-molecular-weight heparin (LMWH), vitamin K antagonist, fondaparinux, or unfractionated heparin; and reporting of mortality outcomes. We did not include trials that compared different thrombolytic agents against one another or different doses of the same thrombolytic drug.
License Information
The use of John Snow Labs datasets is free for personal and research purposes. For commercial use please subscribe to the Data Library on AWS. The subscription will allow you to use all John Snow Labs datasets and data packages for commercial purposes.
Metadata
Description
Value
Data Package Complexity
Simple
Available Enrichments
N/A
Keywords
Anticoagulant Therapy, Hematoma Treatment, Novel Anticoagulants, Chronic Care Model, Chronic Disease Management, Wagner Chronic Care Model, Thrombolytics, Treatment of Pulmonary Embolism, Warfarin Monitoring, Clotting Factors
Other Titles
Patients on Anticoagulant Therapy With and Without Hematoma Enlargement, Chronic Care Anticoagulant Therapy Management, Warfarin Dosage in Anticoagulant Chronic Care Management, Chronic Disease Management and Patient Outcomes, Thrombolysis Treatment for Pulmonary Embolism Complications
Included Datasets
Characteristics of OAC Patients With and Without Hematoma Enlargement
The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed this study on behalf of IGNITE (Initiative of German Neuro Intensive Trial Engagement) and was published by The Journal of the American Medical Association (JAMA) on February 24, 2015. The study investigated the association of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and the effects of OAC resumption.
Chronic Care Management Differences in Anticoagulant Clinics
This research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy. The data were subjected to regression analysis to identify to what extent the differences in patient outcomes are associated with chronic care management activities.
Chronic Care Management Patient Outcomes in Anticoagulant Regions
This research study published in BioMed Central Health Services Research compared the patient outcomes between Dutch Anticoagulant Clinic (AC) regions taking into account the variations in chronic care management (CCM) in order to explore whether these CCM elements could improve the quality of oral anticoagulant therapy (OAT). This study was performed to identify the differences in patient outcomes and their relationship with chronic care management of OAT.
This clinical investigation that was published in The Journal of the American Medical Association (JAMA) on June 18, 2014, was a collaboration of efforts from PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science, and CINAHL since its inception from April 10, 2014.
Pulmonary Embolism Thrombolysis Treatment and Its Complications JAMA
This clinical investigation that was published in The Journal of the American Medical Association (JAMA) on June 18, 2014, was a collaboration of efforts from PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science, and CINAHL since its inception from April 10, 2014. The goal of the study was to determine the risks and complications involved with thrombolytic therapy compared with anticoagulation in acute pulmonary embolism.
Subgroup Analysis for Mode of Reversal Treatment FFP vs PCC
The German-wide Multicenter Analysis of Oral Anticoagulation-associated Intracerebral Hemorrhage (RETRACE) investigators performed this study on behalf of IGNITE (Initiative of German Neuro Intensive Trial Engagement) and was published by The Journal of the American Medical Association (JAMA) on February 24, 2015. The study compared outcome for patients using two different mode of reversal treatments: (1) Fresh Frozen Plasma (FFP), and (2) Prothrombin Complex Concentrates (PCC).
Data Engineering Overview
We deliver high-quality data
Each dataset goes through 3 levels of quality review
2 Manual reviews are done by domain experts
Then, an automated set of 60+ validations enforces every datum matches metadata & defined constraints
Data is normalized into one unified type system
All dates, unites, codes, currencies look the same
All null values are normalized to the same value
All dataset and field names are SQL and Hive compliant
Data and Metadata
Data is available in both CSV and Apache Parquet format, optimized for high read performance on distributed Hadoop, Spark & MPP clusters
Metadata is provided in the open Frictionless Data standard, and its every field is normalized & validated
Data Updates
Data updates support replace-on-update: outdated foreign keys are deprecated, not deleted
Our data is curated and enriched by domain experts
Each dataset is manually curated by our team of doctors, pharmacists, public health & medical billing experts:
Field names, descriptions, and normalized values are chosen by people who actually understand their meaning
Healthcare & life science experts add categories, search keywords, descriptions and more to each dataset
Both manual and automated data enrichment supported for clinical codes, providers, drugs, and geo-locations
The data is always kept up to date – even when the source requires manual effort to get updates
Support for data subscribers is provided directly by the domain experts who curated the data sets
Every data source’s license is manually verified to allow for royalty-free commercial use and redistribution.
John Snow Labs, an AI and NLP for healthcare company, provides state-of-the-art software, models, and data to help healthcare and life science organizations build, deploy, and operate AI projects.
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
This listing uses a single pricing dimension: Product Access (Units). It grants you access to the product at no charge. There are no tiers, instance sizes, or usage add-ons to compare. You subscribe under one flat access option. Because the model is free, your cost does not scale with the number of documents, users, or pipelines you process. You run the software within your own infrastructure and manage access through this one dimension.
Top-of-mind questions for buyers
What does the Product Access (Units) dimension grant, and is there any limit on documents or users?
This dimension grants you access to the product at no charge. There is no limit on the number of characters, words, documents, pipelines, or users you can process. You run the software on your own infrastructure, and access is managed through this single free dimension.
Do I share my data with the vendor when running this product?
No. You install and run the software within your own infrastructure. It does not call home, and no data or results are sent to the vendor. This design supports high-compliance environments handling protected health information or personally identifiable data.
Does the software need an internet connection to run?
After initial installation and downloading of pre-trained models, the core library does not require an internet connection. However, the Healthcare, Visual, Finance, and Legal libraries need a connection to validate your license key when starting a session. For air-gapped deployments, contact the vendor.
Tell us how we can improve this page, or report an issue with this product.
Give us feedbackReport a problem with this product or seller
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA).
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
The Moringa Products Market is growing at a high rate with manufacturers, health brands and retailers looking into enhancing accessibility, quality of the products and consumer interaction via digital and retail channels. New processing technologies, new extraction processes, and uniform quality testing are guaranteeing the retention of more nutrients, increased safety, and uniform product effectiveness.
Pharmaceutical CRM Software Market Size, Trends and Insights By Deployment Type (On-Premises CRM Software, Cloud-Based CRM Software), By Application (Sales Force Automation (Reps), Clinical Trial Solutions (Recruitment, ePRO, EDC), Medical Affairs (KOL engagement, analytics), Pharmacovigilance/R&D), By Customer (Small Enterprise, Medium Enterprise, Large Enterprise), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 - 2034